April 23, 2018
Authored and Edited by Nicholas J. Doyle; Kara A. Specht; Elizabeth D. Ferrill
In Raniere v. Microsoft Corp., the Federal Circuit analyzed what it meant to be a prevailing party under 35 U.S.C. § 285. Section 285 allows for the award of reasonable attorneys’ fees to the prevailing party in exceptional cases.
In response to Raniere’s complaint alleging two counts of patent infringement, Microsoft moved to dismiss the suit for lack of standing after discovering that the PTO’s records indicated that Raniere did not own the patents. After Raniere produced documents and gave testimony regarding the patent ownership, which the district court labeled “wholly incredible and untruthful,” the district court dismissed the case with prejudice. Microsoft moved for and was awarded attorneys’ fees under § 285. Raniere appealed this ruling, claiming that § 285 required a party to succeed on the merits of its case to be the prevailing party.
The Federal Circuit held that success on the merits was not required for a party to be awarded attorneys’ fees. Applying Supreme Court precedent, the Court held that a prevailing party is a party that receives a judicially sanctioned change in the legal relationship of the parties. Thus, the grant of a motion to dismiss would make the moving party the prevailing party under § 285.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada
October 14-16, 2026
New York
Seminar
October 1, 2026
Washington, DC
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.